Log in
NASDAQ:ATRC

AtriCure Stock Forecast, Price & News

$37.96
-0.32 (-0.84 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$37.50
Now: $37.96
$39.45
50-Day Range
$37.86
MA: $40.33
$43.50
52-Week Range
$23.17
Now: $37.96
$51.76
Volume138,200 shs
Average Volume407,238 shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.72
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Read More
AtriCure logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100
Employees730

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$230.81 million
Book Value$6.25 per share

Profitability

Net Income$-35,190,000.00

Miscellaneous

Market Cap$1.71 billion
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$37.96
-0.32 (-0.84 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AtriCure (NASDAQ:ATRC) Frequently Asked Questions

How has AtriCure's stock been impacted by Coronavirus?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATRC stock has increased by 7.6% and is now trading at $37.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AtriCure?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AtriCure
.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for AtriCure
.

How can I listen to AtriCure's earnings call?

AtriCure will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Tuesday, July, 28th. The medical device company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.21. The medical device company had revenue of $40.82 million for the quarter, compared to the consensus estimate of $36.07 million. AtriCure had a negative return on equity of 19.55% and a negative net margin of 23.64%. The firm's revenue was down 30.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.17) EPS.
View AtriCure's earnings history
.

What price target have analysts set for ATRC?

7 brokers have issued twelve-month price targets for AtriCure's shares. Their forecasts range from $45.00 to $60.00. On average, they anticipate AtriCure's share price to reach $52.71 in the next year. This suggests a possible upside of 38.9% from the stock's current price.
View analysts' price targets for AtriCure
.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest in September. As of September 30th, there was short interest totaling 2,230,000 shares, an increase of 18.0% from the September 15th total of 1,890,000 shares. Based on an average daily volume of 337,500 shares, the days-to-cover ratio is presently 6.6 days.
View AtriCure's Short Interest
.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Who are AtriCure's key executives?

AtriCure's management team includes the following people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 49, Pay $1.83M)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 54, Pay $967.43k)
  • Mr. Salvatore Privitera J.D., Chief Technical Officer (Age 53, Pay $639.99k)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 42, Pay $632.13k)
  • Mr. M. Andrew Wade CPA, CPA, Advisor (Age 45, Pay $727.06k)

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.72%), Foundry Partners LLC (0.10%), MAI Capital Management (0.03%), Envestnet Asset Management Inc. (0.03%), Diversified Trust Co (0.02%) and HighMark Wealth Management LLC (0.01%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves.
View institutional ownership trends for AtriCure
.

Which major investors are buying AtriCure stock?

ATRC stock was purchased by a variety of institutional investors in the last quarter, including Foundry Partners LLC, MAI Capital Management, HighMark Wealth Management LLC, Diversified Trust Co, Peregrine Capital Management LLC, Envestnet Asset Management Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for AtriCure
.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $37.96.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.71 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 730 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.